program goals
DESCRIPTION
Program Goals. Introduction. Using Vaccines in the Treatment of NSCLC. Vaccine Approach in NSCLC Targeting Tumor Antigens. Vaccines Evaluated in Phase 3 Lung Cancer Trials Study Designs. Vaccines Evaluated in Phase 3 Lung Cancer Trials (cont) Study Designs. - PowerPoint PPT PresentationTRANSCRIPT
![Page 1: Program Goals](https://reader035.vdocuments.net/reader035/viewer/2022062718/56812c71550346895d9109bd/html5/thumbnails/1.jpg)
![Page 2: Program Goals](https://reader035.vdocuments.net/reader035/viewer/2022062718/56812c71550346895d9109bd/html5/thumbnails/2.jpg)
Program Goals
![Page 3: Program Goals](https://reader035.vdocuments.net/reader035/viewer/2022062718/56812c71550346895d9109bd/html5/thumbnails/3.jpg)
Introduction
![Page 4: Program Goals](https://reader035.vdocuments.net/reader035/viewer/2022062718/56812c71550346895d9109bd/html5/thumbnails/4.jpg)
Using Vaccines in the Treatment of NSCLC
![Page 5: Program Goals](https://reader035.vdocuments.net/reader035/viewer/2022062718/56812c71550346895d9109bd/html5/thumbnails/5.jpg)
Vaccine Approach in NSCLC Targeting Tumor Antigens
![Page 6: Program Goals](https://reader035.vdocuments.net/reader035/viewer/2022062718/56812c71550346895d9109bd/html5/thumbnails/6.jpg)
Vaccines Evaluated in Phase 3 Lung Cancer Trials
Study Designs
![Page 7: Program Goals](https://reader035.vdocuments.net/reader035/viewer/2022062718/56812c71550346895d9109bd/html5/thumbnails/7.jpg)
Vaccines Evaluated in Phase 3 Lung Cancer Trials (cont)
Study Designs
![Page 8: Program Goals](https://reader035.vdocuments.net/reader035/viewer/2022062718/56812c71550346895d9109bd/html5/thumbnails/8.jpg)
Vaccines Evaluated in Phase 3 Lung Cancer Trials
Study Results
![Page 9: Program Goals](https://reader035.vdocuments.net/reader035/viewer/2022062718/56812c71550346895d9109bd/html5/thumbnails/9.jpg)
Vaccines Evaluated in Phase 3 Lung Cancer Trials (cont)
Study Results
![Page 10: Program Goals](https://reader035.vdocuments.net/reader035/viewer/2022062718/56812c71550346895d9109bd/html5/thumbnails/10.jpg)
Using Vaccines in the Treatment of NSCLC: Key Points
![Page 11: Program Goals](https://reader035.vdocuments.net/reader035/viewer/2022062718/56812c71550346895d9109bd/html5/thumbnails/11.jpg)
Immune Checkpoints and Their Inhibition
![Page 12: Program Goals](https://reader035.vdocuments.net/reader035/viewer/2022062718/56812c71550346895d9109bd/html5/thumbnails/12.jpg)
Immune Checkpoint Blockade Approach in NSCLC
Targeting the Immune System
![Page 13: Program Goals](https://reader035.vdocuments.net/reader035/viewer/2022062718/56812c71550346895d9109bd/html5/thumbnails/13.jpg)
CTLA-4: Upregulation and Blockade
![Page 14: Program Goals](https://reader035.vdocuments.net/reader035/viewer/2022062718/56812c71550346895d9109bd/html5/thumbnails/14.jpg)
CTLA-4 in the Immune Response
![Page 15: Program Goals](https://reader035.vdocuments.net/reader035/viewer/2022062718/56812c71550346895d9109bd/html5/thumbnails/15.jpg)
PD-1 and PD-L1 and PD-1/PD-L1 Blockade
![Page 16: Program Goals](https://reader035.vdocuments.net/reader035/viewer/2022062718/56812c71550346895d9109bd/html5/thumbnails/16.jpg)
PD-1/PD-L1 in the Immune Response
![Page 17: Program Goals](https://reader035.vdocuments.net/reader035/viewer/2022062718/56812c71550346895d9109bd/html5/thumbnails/17.jpg)
CTLA-4 and PD-1 Signaling Pathways
![Page 18: Program Goals](https://reader035.vdocuments.net/reader035/viewer/2022062718/56812c71550346895d9109bd/html5/thumbnails/18.jpg)
Antibody Blockade of Immune Checkpoints
![Page 19: Program Goals](https://reader035.vdocuments.net/reader035/viewer/2022062718/56812c71550346895d9109bd/html5/thumbnails/19.jpg)
Immune Checkpoints and Their Inhibition: Key Points
![Page 20: Program Goals](https://reader035.vdocuments.net/reader035/viewer/2022062718/56812c71550346895d9109bd/html5/thumbnails/20.jpg)
Immune-related Response Criteria
![Page 21: Program Goals](https://reader035.vdocuments.net/reader035/viewer/2022062718/56812c71550346895d9109bd/html5/thumbnails/21.jpg)
Evaluating Response to Immunotherapeutic Agents in Solid Tumors
Immune-Related Response Criteria
![Page 22: Program Goals](https://reader035.vdocuments.net/reader035/viewer/2022062718/56812c71550346895d9109bd/html5/thumbnails/22.jpg)
Defining Response WHO vs irRC
![Page 23: Program Goals](https://reader035.vdocuments.net/reader035/viewer/2022062718/56812c71550346895d9109bd/html5/thumbnails/23.jpg)
Defining Response (cont) WHO vs irRC
![Page 24: Program Goals](https://reader035.vdocuments.net/reader035/viewer/2022062718/56812c71550346895d9109bd/html5/thumbnails/24.jpg)
Patterns of Response to Cancer Immunotherapy
![Page 25: Program Goals](https://reader035.vdocuments.net/reader035/viewer/2022062718/56812c71550346895d9109bd/html5/thumbnails/25.jpg)
Immune-related Response Criteria:Key Points
![Page 26: Program Goals](https://reader035.vdocuments.net/reader035/viewer/2022062718/56812c71550346895d9109bd/html5/thumbnails/26.jpg)
Clinical Studies of Immune Checkpoint Inhibitor Therapy in
Advanced NSCLC
![Page 27: Program Goals](https://reader035.vdocuments.net/reader035/viewer/2022062718/56812c71550346895d9109bd/html5/thumbnails/27.jpg)
Ipilimumab + Chemotherapy in Advanced NSCLCDesign of Phase 2 Trial
![Page 28: Program Goals](https://reader035.vdocuments.net/reader035/viewer/2022062718/56812c71550346895d9109bd/html5/thumbnails/28.jpg)
Ipilimumab + Chemotherapy in Advanced NSCLC
Results
![Page 29: Program Goals](https://reader035.vdocuments.net/reader035/viewer/2022062718/56812c71550346895d9109bd/html5/thumbnails/29.jpg)
Ipilimumab + ChemotherapyHistology Subgroup Analysis
![Page 30: Program Goals](https://reader035.vdocuments.net/reader035/viewer/2022062718/56812c71550346895d9109bd/html5/thumbnails/30.jpg)
Anti-PD-1 and Anti-PD-L1 Monotherapy in Heavily Pretreated
Patients With Advanced NSCLCEfficacy in Phase 1 Trials
![Page 31: Program Goals](https://reader035.vdocuments.net/reader035/viewer/2022062718/56812c71550346895d9109bd/html5/thumbnails/31.jpg)
Anti-PD-1 and Anti-PD-L1 Monotherapy in Heavily Pretreated
Patients With Advanced NSCLCSafety in Phase 1 Trials
![Page 32: Program Goals](https://reader035.vdocuments.net/reader035/viewer/2022062718/56812c71550346895d9109bd/html5/thumbnails/32.jpg)
Anti-PD-1 and Anti-PD-L1 Monotherapy in Heavily Pretreated
Patients With Advanced NSCLCSafety in Phase 1 Studies
![Page 33: Program Goals](https://reader035.vdocuments.net/reader035/viewer/2022062718/56812c71550346895d9109bd/html5/thumbnails/33.jpg)
Phase 1 Study of Nivolumab in Heavily Pretreated Pts With
Advanced NSCLCHistology Subgroup Analysis
![Page 34: Program Goals](https://reader035.vdocuments.net/reader035/viewer/2022062718/56812c71550346895d9109bd/html5/thumbnails/34.jpg)
Phase 1 Studies of Single Agent Immunotherapies in First-Line
Setting
![Page 35: Program Goals](https://reader035.vdocuments.net/reader035/viewer/2022062718/56812c71550346895d9109bd/html5/thumbnails/35.jpg)
Combinations With Immunotherapy in Advanced
NSCLC
![Page 36: Program Goals](https://reader035.vdocuments.net/reader035/viewer/2022062718/56812c71550346895d9109bd/html5/thumbnails/36.jpg)
Combinations With Immunotherapy in Advanced
NSCLC (cont)
![Page 37: Program Goals](https://reader035.vdocuments.net/reader035/viewer/2022062718/56812c71550346895d9109bd/html5/thumbnails/37.jpg)
Clinical Studies of Immune Checkpoint Inhibitor Therapy in
Advanced NSCLC: Key Points
![Page 38: Program Goals](https://reader035.vdocuments.net/reader035/viewer/2022062718/56812c71550346895d9109bd/html5/thumbnails/38.jpg)
Tumor PD-L1 Level as a Biomarker for Response
![Page 39: Program Goals](https://reader035.vdocuments.net/reader035/viewer/2022062718/56812c71550346895d9109bd/html5/thumbnails/39.jpg)
Relationship Between PD-L1 Tumor Status and Response to PD-1 and
PD-L1 Inhibitors
![Page 40: Program Goals](https://reader035.vdocuments.net/reader035/viewer/2022062718/56812c71550346895d9109bd/html5/thumbnails/40.jpg)
Relationship Between PD-L1 Tumor Status and Response to PD-1 and
PD-L1 Inhibitors (cont)
![Page 41: Program Goals](https://reader035.vdocuments.net/reader035/viewer/2022062718/56812c71550346895d9109bd/html5/thumbnails/41.jpg)
Other Immune Checkpoint Targets
![Page 42: Program Goals](https://reader035.vdocuments.net/reader035/viewer/2022062718/56812c71550346895d9109bd/html5/thumbnails/42.jpg)
Some Other Immune Checkpoint Protein Targets
![Page 43: Program Goals](https://reader035.vdocuments.net/reader035/viewer/2022062718/56812c71550346895d9109bd/html5/thumbnails/43.jpg)
Some Other Immune Checkpoint Protein Targets (cont)
![Page 44: Program Goals](https://reader035.vdocuments.net/reader035/viewer/2022062718/56812c71550346895d9109bd/html5/thumbnails/44.jpg)
Ongoing Phase 3 Clinical Trials of Immune Checkpoint Inhibitor Therapy in Advanced NSCLC
![Page 45: Program Goals](https://reader035.vdocuments.net/reader035/viewer/2022062718/56812c71550346895d9109bd/html5/thumbnails/45.jpg)
Some Ongoing Phase 3 Trials Second Line
![Page 46: Program Goals](https://reader035.vdocuments.net/reader035/viewer/2022062718/56812c71550346895d9109bd/html5/thumbnails/46.jpg)
Some Ongoing Phase 3 Trials (cont)
Second Line
![Page 47: Program Goals](https://reader035.vdocuments.net/reader035/viewer/2022062718/56812c71550346895d9109bd/html5/thumbnails/47.jpg)
Some Ongoing Phase 3 TrialsFirst Line
![Page 48: Program Goals](https://reader035.vdocuments.net/reader035/viewer/2022062718/56812c71550346895d9109bd/html5/thumbnails/48.jpg)
Program Summary
![Page 49: Program Goals](https://reader035.vdocuments.net/reader035/viewer/2022062718/56812c71550346895d9109bd/html5/thumbnails/49.jpg)
Abbreviations
![Page 50: Program Goals](https://reader035.vdocuments.net/reader035/viewer/2022062718/56812c71550346895d9109bd/html5/thumbnails/50.jpg)
Abbreviations (cont)
![Page 51: Program Goals](https://reader035.vdocuments.net/reader035/viewer/2022062718/56812c71550346895d9109bd/html5/thumbnails/51.jpg)
Abbreviations (cont)
![Page 52: Program Goals](https://reader035.vdocuments.net/reader035/viewer/2022062718/56812c71550346895d9109bd/html5/thumbnails/52.jpg)
Abbreviations (cont)
![Page 53: Program Goals](https://reader035.vdocuments.net/reader035/viewer/2022062718/56812c71550346895d9109bd/html5/thumbnails/53.jpg)
References
![Page 54: Program Goals](https://reader035.vdocuments.net/reader035/viewer/2022062718/56812c71550346895d9109bd/html5/thumbnails/54.jpg)
References (cont)
![Page 55: Program Goals](https://reader035.vdocuments.net/reader035/viewer/2022062718/56812c71550346895d9109bd/html5/thumbnails/55.jpg)
References (cont)
![Page 56: Program Goals](https://reader035.vdocuments.net/reader035/viewer/2022062718/56812c71550346895d9109bd/html5/thumbnails/56.jpg)
References (cont)
![Page 57: Program Goals](https://reader035.vdocuments.net/reader035/viewer/2022062718/56812c71550346895d9109bd/html5/thumbnails/57.jpg)
References (cont)
![Page 58: Program Goals](https://reader035.vdocuments.net/reader035/viewer/2022062718/56812c71550346895d9109bd/html5/thumbnails/58.jpg)
References (cont)
![Page 59: Program Goals](https://reader035.vdocuments.net/reader035/viewer/2022062718/56812c71550346895d9109bd/html5/thumbnails/59.jpg)
References (cont)
![Page 60: Program Goals](https://reader035.vdocuments.net/reader035/viewer/2022062718/56812c71550346895d9109bd/html5/thumbnails/60.jpg)
References (cont)